Cited by 1,074CAR-T cell therapy researchImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.

Engineered T cells: the promise and challenges of cancer immunotherapy

Open access

Fesnak, Andrew D., June, Carl H., Levine, Bruce L.·2016·Nature Reviews Cancer

DOI 10.1038/nrc.2016.97PMC PMC5543811

Open this paper in CoChat — free account

Abstract

The immune system evolved to distinguish non-self from self to protect the organism. As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge. This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumour microenvironment. The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed. Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy. Recent clinical trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory haematological malignancies. In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc.2016.97

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Self-citation
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citation
Antibody therapy of cancer
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citation
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,668
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,597
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Self-citation
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,209
Self-citation
Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P. C., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citation
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Pulè, M. A., Savoldo, B., Myers, G. D., Rössig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,181
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J. V., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J. E., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,175
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,174
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O’Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C. L., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,130
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors
Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.012 · Cited by 1,019
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citation
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela‐Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. Μ., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Self-citation
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 884
Self-citation
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
Sun, L., Hui, A.-M., Su, Q., Vortmeyer, A. O., Kotliarov, Y., Pastorino, S., Passaniti, A., Menon, J., Walling, J., Bailey, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.003 · Cited by 883
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 880
Self-citation
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 824
Isolation of cancer stem cells from adult glioblastoma multiforme
Yuan, X., Curtin, J. F., Xiong, Y., Liu, G., Wachsmann‐Hogiu, S., Farkas, D. L., Black, K. L., & Yu, J. S. (2004) · Oncogene · doi:10.1038/sj.onc.1208311 · Cited by 814
The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways
Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 806
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J. R., Wright, C. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 766
PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 752
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Chang, K., & Pastan, I. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 747
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., OSSENDORP, F. A., van Hall, T., & Melief, C. J. M. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.16 · Cited by 731
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Till, B. G., Jensen, M. C., Wang, J., Chen, E., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A. A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 721
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 711
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C. C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Serio, C. D., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 709
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 706
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 699
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 686
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T., Binder-Scholl, G. K., Hwang, W., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M. D., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 653
Self-citation
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 641
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504542 · Cited by 624
Self-citation
Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 605
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. Μ., Levine, B. L., Liu, X., Zhao, Y., Kalos, M. D., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 596
Self-citation
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 592
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 583
Self-citation
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Adusumilli, P. S., Cherkassky, L., Villena‐Vargas, J., Colovos, C., Servais, E. L., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 582
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W. M., Lee, D. W., Shah, N. N., Stetler‐Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 579
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 567
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Hudecek, M., Stanghellini, M. T. L., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C. M., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 557
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J. A., Greipp, P. R., & Jelinek, D. F. (2003) · Blood · doi:10.1182/blood-2003-06-2043 · Cited by 556
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 545
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 545
Self-citation
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Till, B. G., Jensen, M. C., Wang, J., Qian, X., Gopal, A. K., Maloney, D. G., Lindgren, C. G., Lin, Y., Pagel, J. M., Budde, L. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-387969 · Cited by 535
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 535
Self-citation
Anti-Transgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Re-directed T Cells in Humans
Jensen, M., Popplewell, L., Cooper, L., Digiusto, D., Kalos, M., Ostberg, J., & Forman, S. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 522
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Cruz, C. C., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 515
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
Craddock, J. A., Lu, A., Bear, A. S., Pulè, M. A., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 514
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
Avery, D. T., Kalled, S. L., Ellyard, J. I., Ambrose, C. M., Bixler, S. A., Thien, M., Brink, R. A., Mackay, F., Hodgkin, P. D., & Tangye, S. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18025 · Cited by 510
Gene transfer in humans using a conditionally replicating lentiviral vector
Levine, B. L., Humeau, L. M. P. F., Boyer, J., MacGregor, R.-R., Rebello, T., Lü, X., Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608138103 · Cited by 505
Self-citation
Immune Regulation of Cancer
Disis, M. L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2146 · Cited by 504
The basic biology of HER2
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 502
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
Gill, S. I., Tasian, S. K., Ruella, M., Shestova, O. E., Li, Y., Porter, D. L., Carroll, M. P., Danet-Desnoyers, G. A., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 498
Self-citation
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. F. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 491
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
Pulè, M. A., Straathof, K. C. M., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 486
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Self-citation
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M. G., Byrd, T. T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 469
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 469
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., & Livingston, R. B. (1994) · PubMed · Cited by 464
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A., Dentchev, T., Thekkat, P. U., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 459
Self-citation
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
Zhao, Y., Moon, E. K., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 458
Self-citation
Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer
Webb, J. R., Milne, K., Watson, P. H., deLeeuw, R. J., & Nelson, B. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 447
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
Kenderian, S. S., Ruella, M., Shestova, O. E., Klichinsky, M., Aikawa, V., Morrissette, J. J. D., Scholler, J., Song, D., Porter, D., Carroll, M. P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 435
Self-citation
Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 432
Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects
Mitsuyasu, R. T., Anton, P. A., Deeks, S. G., Scadden, D. T., Connick, E., Downs, M. T., Bakker, A., Roberts, M. R., June, C. H., Jalali, S., et al. (2000) · Blood · doi:10.1182/blood.v96.3.785.015k10_785_793 · Cited by 431
Self-citation
Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity
Billingham, R. E., Brent, L., & MEDAWAR, P. B. (1954) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1954.0054 · Cited by 428
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Wang, Q., Wang, Y., Lv, H., Han, Q., Fan, H., Guo, B., Wang, L.-L., & Han, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 424
The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Gargett, T., & Brown, M. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00235 · Cited by 418
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Caruso, H. G., Hurton, L. V., Najjar, A. M., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K. C., Singh, H., Huls, H. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 410
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K. C. M., Flutter, B. R., Marin, V., Marafioti, T., Chakraverty, R. K., Linch, D. C., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 408
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y. J., Ramadoss, N. S., Hardy, I. R., Schulman, A. D., Du, J., Wang, F., Singer, O., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524155113 · Cited by 404
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
Romeo, C., & Seed, B. (1991) · Cell · doi:10.1016/0092-8674(91)90327-u · Cited by 396
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Furnari, F. B., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3918 · Cited by 389
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Ahmed, N. M., Salsman, V. S., Kew, Y., Shaffer, D. R., Powell, S. Z.-E., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 387
Application of Mesothelin Immunostaining in Tumor Diagnosis
Ordóǹez, N. G. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200311000-00003 · Cited by 383
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Mardiros, A., Santos, C. D., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., Hoffman, L., Aguilar, B., Chang, W.-C., Bretzlaff, W. S., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474056 · Cited by 381
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A. L.-T., Staffileno, L. K., & Reisfeld, R. A. (1984) · PubMed · Cited by 368
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
Casucci, M., di Robilant, B. N., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 363
APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity
Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M. J., Ramakrishnan, M., McCabe, S., Qiu, W., Kornuc, M., Xia, X.-Z., et al. (2000) · Nature Immunology · doi:10.1038/79802 · Cited by 362
Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma
Dudley, M. E., Wunderlich, J. R., Nishimura, M. I., Yu, D. C., Yang, J. C.-H., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Sherry, R. M., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200107000-00012 · Cited by 361
Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Crompton, J. G., Sukumar, M., Roychoudhuri, R., Clever, D. C., Gros, A., Eil, R. L., Tran, E., Hanada, K., Yu, Z., Palmer, D. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2277 · Cited by 354
A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015) · Blood · doi:10.1182/blood-2015-02-629527 · Cited by 341
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D.-G., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 339
Self-citation
Mesothelin targeted cancer immunotherapy.
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 337
Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 328
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 327
CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy
Scheuermann, R. H., & Racila, E. V. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509059636 · Cited by 323
Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C. H.-L., Zhou, Y., Crossland, D. L., Huls, H. M., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 312
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 310
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Koneru, M., O'Cearbhaill, R. E., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0460-x · Cited by 309
T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins.
Letourneur, F., & Klausner, R. D. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.8905 · Cited by 308
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M. A., Bornstein, G. G., & Suria, H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 307
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
Sampson, J. H., Choi, B. D., Sanchez-Perez, L. A., Suryadevara, C. M., Snyder, D. J., Flores, C., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 299
Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 297
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
Pizzitola, I., Anjos‐Afonso, F., Rouault‐Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. A. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 291
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B. C., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 284
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Vera, J. F., Savoldo, B., Vigouroux, S., Biagi, E., Pulè, M. A., Rössig, C., Wu, J. M., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 276
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz, L., Nomdedeu, J. F., López, O., et al. (2001) · PubMed · Cited by 274
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium
Chang, K., Pastan, I. H., & Willingham, M. C. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500308 · Cited by 271
Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation
Mammadova‐Bach, E., Ollivier, V., Loyau, S., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629717 · Cited by 268
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Cheung, N. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. I. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 267
The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
Ordóǹez, N. G. (2003) · Modern Pathology · doi:10.1097/01.mp.0000056981.16578.c3 · Cited by 264
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Chodon, T., Comı́n-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E. V., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 264
Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
Hong, M. L. W., Puaux, A., Huang, C. W., Loumagne, L., Tow, C., Mackay, C. R., Kato, M., Prévost‐Blondel, A., Avril, M., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 262
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
Mujoo, K., Cheresh, D. A., Yang, H. M., et al. (1987) · PubMed · Cited by 247
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia
Baskar, S., Kwong, K. Y., Höfer, T., Levy, J. M., Kennedy, M. G., Lee, E., Staudt, L. M., Wilson, W. H., Wiestner, A. U., & Rader, C. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1823 · Cited by 238
Mesothelin Is Overexpressed in Pancreaticobiliary Adenocarcinomas But Not in Normal Pancreas and Chronic Pancreatitis
Hassan, R., Laszik, Z. G., Lerner, M. R., Raffeld, M. A., Postier, R. G., & Brackett, D. J. (2005) · American Journal of Clinical Pathology · doi:10.1309/f1b64cl7h8vjkeaf · Cited by 235
Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells
Brown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martínez, C., D’Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 227
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.
WALKER, R. E., Bechtel, C. M., Natarajan, V., Baseler, M., Hege, K. M., Metcalf, J. A., Stevens, R. A., Hazen, A., Blaese, R. M., Chen, C. C., et al. (2000) · PubMed · doi:10.1182/blood.v96.2.467 · Cited by 225
Self-citation
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
Rossi, D., di Bergamo, L. T., Paoli, L. D., Cerri, M., Ghilardi, G., Chiarenza, A., Bulian, P., Visco, C., Mauro, F. R., Morabito, F., et al. (2015) · Blood · doi:10.1182/blood-2015-05-647925 · Cited by 216
Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains
Wang, J., Jensen, M. C., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B. G., Raubitschek, A. A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 216
Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor
Foster, A. E., Dotti, G., Lu, A., Khalil, M., Brenner, M. K., Heslop, H. E., Rooney, C. M., & Bollard, C. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177092b · Cited by 210
Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas
Palma, L., Lorenzo, N. D., & Guidetti, B. (1978) · Journal of neurosurgery · doi:10.3171/jns.1978.49.6.0854 · Cited by 209
CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma
Guo, B., Chen, M., Han, Q., Hui, F., Dai, H., Zhang, W., Zhang, Y., Wang, Y., Zhu, H., & Han, W. (2015) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2014.11.001 · Cited by 195
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
van Rhee, F., Szmania, S. M., Zhan, F., Gupta, S. K., Pomtree, M., Lin, P. Y., Batchu, R. B., Moreno, A., Spagnoli, G. C., Shaughnessy, J. D., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3707 · Cited by 195
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Ahmed, N. M., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192
Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
Budde, L. E., Berger, C., Lin, Y., Wang, J., Lin, X., Frayo, S. E., Brouns, S. A., Spencer, D. M., Till, B. G., Jensen, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082742 · Cited by 191
Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord
Svennerholm, L. T., Boström, K., Fredman, P., Jungbjer, B., Lekman, A. Y., Månsson, J., & Rynmark, B. (1994) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)90034-5 · Cited by 190
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P. A., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 190
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
Zhang, S., Cui, B., Lai, S. H., Liu, G., Ghia, E. M., Widhopf, G. F., Zhang, Z., Wu, C. C. N., Chen, L., Wu, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419599111 · Cited by 188
Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells
Lynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 185
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.
Joshi, B. H., Plautz, G. E., & Puri, R. K. (2000) · PubMed · Cited by 185
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J. M., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H. E., Rooney, C. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 183
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody
Dao, T., Yan, S., Veomett, N. J., Pankov, D., Zhou, L. L., Korontsvit, T., Scott, A., Whitten, J. A., Maslak, P. G., Casey, E. R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005661 · Cited by 183
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Kachala, S. S., Bograd, A. J., Villena‐Vargas, J., Suzuki, K., Servais, E. L., Kadota, K., Chou, J. F., Sima, C. S., Vertes, E. L., Rusch, V. W., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1862 · Cited by 181
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Tchou, J. C., Wang, L.-C., Selven, B., Zhang, H., Conejo-Garcia, J. R., Borghaei, H., Kalos, M. D., Vondeheide, R. H., Albelda, S. Μ., June, C. H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2018-4 · Cited by 178
Self-citation
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Daneshmanesh, A. H., Mikaelsson, E., Jeddi‐Tehrani, M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23587 · Cited by 177
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 174
Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
Singh, H., Figliola, M. J., Dawson, M. J., Olivares, S., Zhang, L., Yang, G., Maiti, S. N., Manuri, P. R., Senyukov, V., Jena, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064138 · Cited by 174
Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells
Palma, M. D., Montini, E., de Sio, F. R. S., Benedicenti, F., Gentile, A., Médico, E., & Naldini, L. (2004) · Blood · doi:10.1182/blood-2004-03-0798 · Cited by 174
Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia
Bicocca, V. T., Chang, B. H., Masouleh, B. K., Müschen, M., Loriaux, M., Druker, B. J., & Tyner, J. W. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.027 · Cited by 171
Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
Kim, M. S., Ma, J. S. Y., Yun, H., Cao, Y. J., Kim, J. Y., Chi, V., Wang, D., Woods, A. C., Sherwood, L., Caballero, D., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b00106 · Cited by 170
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027469 · Cited by 168
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu, M.-F., Liu, H., Kenney, S. C., et al. (2011) · Blood · doi:10.1182/blood-2010-04-278218 · Cited by 165
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
Pegram, H. J., Purdon, T. J., van Leeuwen, D. G., Curran, K. J., Giralt, S., Barker, J. N., & Brentjens, R. J. (2014) · Leukemia · doi:10.1038/leu.2014.215 · Cited by 161
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
Zhu, X., Prasad, S., Gaedicke, S., Hettich, M., Firat, E., & Niedermann, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2767 · Cited by 159
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells
Hauswirth, A. W., Florian, S., Printz, D., Sotlar, K., Krauth, M. T., Fritsch, G., Schernthaner, G.-H., Wacheck, V., Selzer, E., Sperr, W. R., et al. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01746.x · Cited by 159
The HLA crossroad in tumor immunology
Algarra, I., Cabrera, T., & Garrido, F. (2000) · Human Immunology · doi:10.1016/s0198-8859(99)00156-1 · Cited by 158
CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
Chmielewski, M. M., & Abken, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1202-z · Cited by 141
piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies
Manuri, P. R., Wilson, M. H., Maiti, S. N., Mi, T., Singh, H., Olivares, S., Dawson, M. J., Huls, H. M., Lee, D. A., Rao, P. H., et al. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.114 · Cited by 141
Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells
Yvon, E. S., Vecchio, M. D., Savoldo, B., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3163 · Cited by 141
Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)
Grupp, S. A., Maude, S. L., Shaw, P. A., Aplenc, R., Barrett, D. M., Callahan, C. A., Lacey, S. F., Levine, B. L., Melenhorst, J. J., Motley, L. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.681.681 · Cited by 140
Self-citation
Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Jarboe, J. S., Johnson, K. R., Choi, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1493 · Cited by 139
Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., & Comoglio, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2662 · Cited by 138
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
Brenner, H., Gondos, Á., & Pulte, D. D. (2008) · Blood · doi:10.1182/blood-2007-12-129379 · Cited by 135
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M. H., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26286 · Cited by 134
PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor
Nakazawa, Y., Huye, L. E., Salsman, V. S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.131 · Cited by 127
Large-Scale Production of CD4+ T Cells from HIV-1-Infected Donors After CD3/CD28 Costimulation*
Levine, B. L., Cotte, J., SMALL, C. C., Carroll, R. G., Riley, J. L., Bernstein, W. B., Epps, D. E. V., Hardwick, R. A., & June, C. H. (1998) · Journal of Hematotherapy · doi:10.1089/scd.1.1998.7.437 · Cited by 125
Self-citation
EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
Miao, H., Choi, B. D., Suryadevara, C. M., Sanchez-Perez, L. A., Yang, S., Leon, G. D., Sayour, E. J., McLendon, R. E., Herndon, J. E., Healy, P. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094281 · Cited by 122
Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice
Parente‐Pereira, A. C., Burnet, J., Ellison, D. H., Foster, J., Davies, D. M., van der Stegen, S. J. C., Papa, S., Chiapero-Stanke, L., Wilkie, S., Mather, S. J., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9532-8 · Cited by 118
Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
Byrd, J. C., Jones, J. J., Woyach, J. A., Johnson, A. J., & Flynn, J. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.8262 · Cited by 117
Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 113
Self-citation
The Inside Out of Lentiviral Vectors
Durand, S., & Cimarelli, A. (2011) · Viruses · doi:10.3390/v3020132 · Cited by 112
Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction
Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S. S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7209 · Cited by 112
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas
Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S. X., Albert, C. M., Moy, F., Sachdev, D., Yee, D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133152 · Cited by 109
Ganglioside GD2 in reception and transduction of cell death signal in tumor cells
Doronin, I. I., Vishnyakova, P., Kholodenko, I. V., Ponomarev, E. D., Ryazantsev, D. Y., Molotkovskaya, I. M., & Kholodenko, R. V. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-295 · Cited by 106
Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies
Kebriaei, P., Huls, H. M., Jena, B., Munsell, M. F., Jackson, R. N., Lee, D. A., Hackett, P. B., Rondón, G., Shpall, E. J., Champlin, R. E., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.167 · Cited by 103
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
Bellucci, R., Alyea, E. P., Chiaretti, S., Wu, C. J., Zorn, E., Weller, E. A., Wu, B., Canning, C. M., Schlossman, R. L., Munshi, N. C., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4463 · Cited by 101
First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL
Qasim, W., Amrolia, P. J., Samarasinghe, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2046.2046 · Cited by 98
CD28z CARs and Armored CARs
Pegram, H. J., Park, J. H., & Brentjens, R. J. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000034 · Cited by 93
Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumors
Kawakami, M., Kawakami, K., Takahashi, S., et al. (2004) · Cancer · doi:10.1002/cncr.20470 · Cited by 87
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
Zhao, Q., Ahmed, M., Tassev, D. V., Hasan, A., Kuo, T.-Y., Guo, H.-F., O’reilly, R. J., & Cheung, N. K. (2015) · Leukemia · doi:10.1038/leu.2015.125 · Cited by 85
Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment
Beatty, G. L., & Moon, E. K. (2014) · OncoImmunology · doi:10.4161/21624011.2014.970027 · Cited by 84

Sorted by citations

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Self-citation
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response
Kim, O. Y., Park, H. T., Dinh, N. T. H., Choi, S. J., Lee, J., Kim, J. H., Lee, S.-W., & Gho, Y. S. (2017) · Nature Communications · doi:10.1038/s41467-017-00729-8 · Cited by 616

See all 1,074

Authors: Fesnak, A. D., June, C. H., & Levine, B. L.
Affiliations: University of Pennsylvania (US)
Corresponding author: Fesnak, Andrew D.
Levine, Bruce L.
ORCID: Fesnak, Andrew D.
June, Carl H.
Levine, Bruce L.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2016-08-23
Volume: 16
Issue: 9
Pages: 566-581
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc.2016.97
PMC: PMC5543811
OpenAlex: W2515679023
Cited by: 1,074
References: 251
Citations by year: 2026: 55 · 2025: 76 · 2024: 73 · 2023: 71 · 2022: 91 · 2021: 144 · 2020: 134 · 2019: 127 · 2018: 161 · 2017: 122 · 2016: 13
FWCI: 14.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Parker Foundation
Leukemia and Lymphoma Society
National Institutes of Health
National Heart, Lung, and Blood Institute (T32HL007775)
National Cancer Institute (R01CA165206, R01CA120409, P30CA016520)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: engineered T cells, adoptive cell transfer, cancer immunotherapy, chimeric antigen receptor, engineered T cell receptors, B-cell malignancies, hematologic malignancies, solid tumors, tumor immune evasion, tumor microenvironment, immune tolerance
MeSH terms: Gene Editing, Antigens, Neoplasm, Clinical Trials as Topic, Forecasting, Genetic Engineering, HLA Antigens, Humans, Neoplasms, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, Syndrome, T-Lymphocyte Subsets, Cytokines, Immunotherapy, Adoptive, Antigen Presentation, Gene Transfer Techniques, Models, Immunological, Antigens, CD19, Tumor Escape, Hematologic Neoplasms, T-Cell Antigen Receptor Specificity, Tumor Microenvironment, Costimulatory and Inhibitory T-Cell Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Engineered T cells: the promise and challenges of cancer immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks